Bicycle Therapeutics plc: proceeds from issuing common stock
Proceeds from issuing common stock for Bicycle Therapeutics plc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Bicycle Therapeutics plc financial histories
What this measure means
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
Exact concept: us-gaap:ProceedsFromIssuanceOfCommonStock. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2024-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-01-01 | 2024-12-31 | 544,127,000 | USD | 2026-03-17 | 10-K · 0001104659-26-028971 |
| 2023-01-01 | 2023-12-31 | 249,345,000 | USD | 2026-03-17 | 10-K · 0001104659-26-028971 |
| 2022-01-01 | 2022-12-31 | 5,703,000 | USD | 2025-02-25 | 10-K · 0001558370-25-001438 |
| 2021-01-01 | 2021-12-31 | 290,984,000 | USD | 2024-02-20 | 10-K · 0001558370-24-001324 |
| 2020-01-01 | 2020-12-31 | 48,144,000 | USD | 2023-02-28 | 10-K · 0001558370-23-002238 |
Related financial histories
- Bicycle Therapeutics plc: total assets
- Bicycle Therapeutics plc: total liabilities
- Bicycle Therapeutics plc: stockholders equity
- Bicycle Therapeutics plc: cash and cash equivalents
- Bicycle Therapeutics plc: net income or loss
- Bicycle Therapeutics plc: operating cash flow
- Bicycle Therapeutics plc: capital expenditure payments
- Bicycle Therapeutics plc: contract revenue excluding tax
- Bicycle Therapeutics plc: financing cash flow
- Bicycle Therapeutics plc: investing cash flow
- Bicycle Therapeutics plc: retained earnings or deficit
- Bicycle Therapeutics plc: basic weighted-average shares
- Bicycle Therapeutics plc: diluted weighted-average shares
- Bicycle Therapeutics plc: basic earnings per share
- Bicycle Therapeutics plc: diluted earnings per share
- Bicycle Therapeutics plc: income tax expense or benefit
- Bicycle Therapeutics plc: net property, plant and equipment
- Bicycle Therapeutics plc: share-based compensation expense
- Bicycle Therapeutics plc: operating income or loss
- Bicycle Therapeutics plc: current assets
- Bicycle Therapeutics plc: interest expense
- Bicycle Therapeutics plc: current liabilities
- Bicycle Therapeutics plc: current accounts payable
- Bicycle Therapeutics plc: net current accounts receivable
- Bicycle Therapeutics plc: operating expenses
- Bicycle Therapeutics plc: research and development expense
- Bicycle Therapeutics plc: common shares outstanding
- Bicycle Therapeutics plc: cash including restricted cash
- Bicycle Therapeutics plc: additional paid-in capital
- Bicycle Therapeutics plc: accumulated other comprehensive income or loss
- Bicycle Therapeutics plc: operating lease right-of-use asset
- Bicycle Therapeutics plc: operating lease liability
- Bicycle Therapeutics plc: long-term debt
- Bicycle Therapeutics plc: gross property, plant and equipment
- Bicycle Therapeutics plc: accumulated depreciation on property, plant and equipment
- Bicycle Therapeutics plc: other noncurrent assets
- Bicycle Therapeutics plc: other noncurrent liabilities
- Bicycle Therapeutics plc: accrued current liabilities
- Bicycle Therapeutics plc: prepaid expenses and other current assets
- Bicycle Therapeutics plc: pre-tax income or loss from continuing operations
- Bicycle Therapeutics plc: profit or loss including noncontrolling interests
- Bicycle Therapeutics plc: comprehensive income or loss
- Bicycle Therapeutics plc: net income available to common stockholders
- Bicycle Therapeutics plc: general and administrative expense
- Bicycle Therapeutics plc: depreciation expense
- Bicycle Therapeutics plc: depreciation, depletion and amortization
- Bicycle Therapeutics plc: nonoperating interest expense
- Bicycle Therapeutics plc: other nonoperating income or expense
- Bicycle Therapeutics plc: nonoperating income or expense
- Bicycle Therapeutics plc: current income tax expense or benefit
- Bicycle Therapeutics plc: deferred income tax expense or benefit
- Bicycle Therapeutics plc: interest paid, net
- Bicycle Therapeutics plc: income taxes paid, net
- Bicycle Therapeutics plc: operating lease payments
- Bicycle Therapeutics plc: change in accounts receivable
- Bicycle Therapeutics plc: change in accounts payable
Inspect the source
- Entity
- Bicycle Therapeutics plc / CIK 0001761612
- Captured
- 2026-09-21T17:26:26.173Z
- SEC response SHA-256
02555c68153c7d2a75ed4122501846e3667beeaef014d3a19014e091ce24f986
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001761612.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))